TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18023600

Group type: COMPARATOR
Intervention: Ipratropium bromide 40 mcg inhaled via MDI
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 mcg inhaled via MDI plus ondansetron 8 mg oral, qid, for 2 days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Ipratropium bromide placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ondansetron (single or repeated doses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: sGaw
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: FVC
Number of subjects: 47
Study: 16448522

Group type: EXPERIMENTAL
Intervention: Gliclazide MR (once-daily administration)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Gliclazide (twice-daily administration)
Number of subjects: 63
Study: 14671407

Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2) per day (group A, n = 41)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 2 mg GH/m(2) per day (group B, n = 38)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2) per day (n = 60)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: GH therapy (1 mg or 2 mg GH/m(2) per day)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: After discontinuation of GH therapy
Number of subjects: 165
Study: 14628975

Group type: EXPERIMENTAL
Intervention: 30-minute aerobic endurance exercise at 60% workload
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 30-minute aerobic endurance exercise at 40% workload
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 24
Study: 10193729

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily for two weeks (phase I)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Simvastatin average dose of 24 mg/d for three months (phase II)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day added to simvastatin for two weeks (phase III)
Number of subjects: 33
Study: 8589659

Group type: EXPERIMENTAL
Intervention: Bithermal caloric stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional caloric irrigation
Number of subjects: 0
Study: 1975526

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (calcium antagonist)
Number of subjects: 0
Study: 342313

Group type: EXPERIMENTAL
Intervention: Inactivated whole‐virus vaccine (H0N2)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1200
Study: 31495497

Group type: EXPERIMENTAL
Intervention: Inebilizumab (300 mg intravenous on days 1 and 15)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 230
Study: 28342402

Group type: EXPERIMENTAL
Intervention: Mindful-learning group
Number of subjects: 253

Group type: COMPARATOR
Intervention: Mindfulness condition
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Mindfulness group
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Mindful-learning condition
Number of subjects: 253
Study: 24917557

Group type: EXPERIMENTAL
Intervention: Unripe apple preparation containing phlorizin
Number of subjects: 6
Study: 23627791

Group type: EXPERIMENTAL
Intervention: Wound-specific oral nutrition supplement (enriched with arginine, vitamin C, and zinc)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard oral nutrition supplement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wound-specific oral nutrition supplement
Number of subjects: 24
Study: 20887370

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lorazepam (LZP) 2 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19371826

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (IGC) (n = 25; glucose 80 to 140 mg/dl)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional glycemic control (CGC) (n = 25; glucose 180 to 200 mg/dl)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Hyperglycemic patients compared to normoglycemic patients
Number of subjects: 88
Study: 17693686

Group type: EXPERIMENTAL
Intervention: Gatorade
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Apfelschorle
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: San Benedetto mineral water
Number of subjects: 8

Group type: COMPARATOR
Intervention: Evian mineral water
Number of subjects: 8
Study: 15155310

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Uncoated circuit (Group 2)
Number of subjects: 51
Study: 11686425

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 48
Study: 10410575

Group type: EXPERIMENTAL
Intervention: Glucosamine levels in patients with MI without diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucosamine levels in patients with MI with diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid indexes in patients with MI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of glucosamine levels and glucose concentrations in patients without diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin levels in patients with hyperinsulinemia
Number of subjects: 0
Study: 8290386

Group type: EXPERIMENTAL
Intervention: Nilutamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: D-Trp-6-LHRH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy age-matched controls)
Number of subjects: 12
Study: 2845769

Group type: EXPERIMENTAL
Intervention: CAMP (cyclophosphamide 300 mg/m2 i.v., adriamycin 20 mg/m2 i.v., methotrexate 15 mg/m2 i.v. days 1 and 8, procarbazine 100 mg/m2 orally from day 1 to day 10, every 4 weeks)
Number of subjects: 133

Group type: COMPARATOR
Intervention: DE (cisplatin 20 mg/m2 i.v. for five consecutive days and etoposide 75 mg/m2 i.v. on the same days, every 3 weeks)
Number of subjects: 133

Group type: COMPARATOR
Intervention: DE
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: CAMP
Number of subjects: 133
Study: 31896735

Group type: EXPERIMENTAL
Intervention: Vibratory positional therapy (PT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patient treatment preference
Number of subjects: 40
Study: 31320726

Group type: EXPERIMENTAL
Intervention: CAVA device (Continuous Ambulatory Vestibular Assessment), worn near continuously for up to thirty days, with daily replacement of electrodes.
Number of subjects: 17
Study: 28059849

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin 60 mg/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Moderate statin therapy (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both intensive and moderate statin therapy
Number of subjects: 69
Study: 26016171

Group type: EXPERIMENTAL
Intervention: Fatigue countermeasures
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Fatigue-avoidance strategies
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Call-shift fatigue
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Medical errors due to fatigue
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Hours to recovery from a call shift
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Working 5 to 6 calls per month
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Working 7 or more calls per month
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Use of fatigue countermeasures
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Fatigue symptoms
Number of subjects: 325
Study: 24028358

Group type: EXPERIMENTAL
Intervention: Multidimensional team-based intervention featuring musical cues
Number of subjects: 1928

Group type: COMPARATOR
Intervention: Comparison facilities (no musical cues)
Number of subjects: 1928
Study: 21332970

Group type: EXPERIMENTAL
Intervention: Cyclopentolate hydrochloride 1%
Number of subjects: 50

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 50
Study: 19298689

Group type: EXPERIMENTAL
Intervention: Quinine (600 mg single dose) with nevirapine (200 mg every 12 h for 12 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Quinine (600 mg single dose) alone
Number of subjects: 14
Study: 17974278

Group type: EXPERIMENTAL
Intervention: Nadaplatin 30 mg/m2 dl‐3, paclitaxol 175 mg/m2 dl, repeated every 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cisplatin 30 mg/m2 dl‐3, paclitaxol 175 mg/m2 dl, repeated every 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nadaplatin combined with paclitaxol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cisplatin combined with paclitaxol
Number of subjects: 60
Study: 15590950

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 674

Group type: COMPARATOR
Intervention: Control (no ICD therapy)
Number of subjects: 674
Study: 11561110

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection of triamcinolone hexacetonide and xylocaine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Palpation-guided injection of triamcinolone hexacetonide and xylocaine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 23

Group type: COMPARATOR
Intervention: Palpation-guided injection
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection and palpation-guided injection
Number of subjects: 23
Study: 9460098

Group type: EXPERIMENTAL
Intervention: Schizophrenic subjects
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal subjects (N = 15)
Number of subjects: 29
Study: 7888605

Group type: EXPERIMENTAL
Intervention: Monolithic enteric coated (MEC) diclofenac products
Number of subjects: 16

Group type: COMPARATOR
Intervention: Two mutually most differing MEC diclofenac products
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MEC diclofenac product with low tlag
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MEC diclofenac product with long tlag
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: In vitro dissolution tests at pH 5
Number of subjects: 16
Study: 3062043

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30973454

Group type: EXPERIMENTAL
Intervention: Continuation ECT (4 weekly sessions, followed by 4 sessions every 2 weeks, and 2 monthly sessions for a total of 10 sessions)
Number of subjects: 0
Study: 28478315

Group type: EXPERIMENTAL
Intervention: web intervention plus text messaging (WI+TXT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: assessment only (AO)
Number of subjects: 113

Group type: COMPARATOR
Intervention: web intervention (WI)
Number of subjects: 113
Study: 25251838

Group type: EXPERIMENTAL
Intervention: Immediate treatment group (MSoBT program)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist group (usual care)
Number of subjects: 50
Study: 22594689

Group type: EXPERIMENTAL
Intervention: Early supported discharge in a day unit
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Early supported discharge at home
Number of subjects: 350

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 350
Study: 21459855

Group type: EXPERIMENTAL
Intervention: Blood culture bottle culture
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard culture
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control fluids
Number of subjects: 62
Study: 17373978

Group type: EXPERIMENTAL
Intervention: 308-nm xenon chloride excimer laser therapy + topical calcipotriol (Daivonex) applied twice daily to one side of the body
Number of subjects: 10

Group type: COMPARATOR
Intervention: 308-nm xenon chloride excimer laser therapy alone
Number of subjects: 10
Study: 16312168

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fluticasone propionate
Number of subjects: 42
Study: 12190715

Group type: EXPERIMENTAL
Intervention: Immediate multi-family psychoeducation groups (MFPG) plus treatment as usual (TAU)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wait-list + treatment as usual (TAU)
Number of subjects: 35
Study: 9523850

Group type: EXPERIMENTAL
Intervention: 125 mg i.v. methylprednisolone before and saline after TDI (group 2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 125 mg i.v. methylprednisolone before and after TDI (group 3)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Normal saline before and after TDI (group 1)
Number of subjects: 65
Study: 7666914

Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg/day)
Number of subjects: 72
Study: 2669346

Group type: EXPERIMENTAL
Intervention: Quinine sulfate 200 mg by mouth at bedtime
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1089885

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion obtained from a single donor each day for four days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 36
Study: 30048511

Group type: EXPERIMENTAL
Intervention: serious gaming only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: verbal suggestions only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: serious gaming combined with verbal suggestions
Number of subjects: 120

Group type: COMPARATOR
Intervention: gaming control condition
Number of subjects: 120
Study: 25043636

Group type: EXPERIMENTAL
Intervention: Pulmicort Turbuhaler (DPI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aeronide inhaler (pMDI)
Number of subjects: 36
Study: 24526136

Group type: EXPERIMENTAL
Intervention: 33 μg/kg/day growth hormone (GH) for 260 weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 67 μg/kg/day growth hormone (GH) for 260 weeks
Number of subjects: 65
Study: 23047085

Group type: EXPERIMENTAL
Intervention: Stress management program (3 hours)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: First group of the stress management program
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Second group of the stress management program
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stress management intervention
Number of subjects: 55
Study: 20140250

Group type: COMPARATOR
Intervention: oleic acid
Number of subjects: 61

Group type: COMPARATOR
Intervention: industrial trans fatty acids
Number of subjects: 61

Group type: COMPARATOR
Intervention: 80% cis‐9, trans‐11 and 20% trans‐10, cis‐12 CLA
Number of subjects: 61
Study: 18568968

Group type: EXPERIMENTAL
Intervention: Operational motion of the thumb
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Circumduction of the thumb
Number of subjects: 15
Study: 16599106

Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Micronutrient-fortified corn/soy-blend
Number of subjects: 372
Study: 14721990

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 65

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 65
Study: 10982756

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8791975

Group type: EXPERIMENTAL
Intervention: Sucralfate gel (1 g b.d.)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 1292969

Group type: EXPERIMENTAL
Intervention: Erdosteine (900 mg/day for two weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Erdosteine (pre-incubation before smoke exposure)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6712032

Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg orally twice a day for 7 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31511705

Group type: EXPERIMENTAL
Intervention: Manual intervertebral foramen opening technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manual traction of cervical spine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of both techniques
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 29898348

Group type: EXPERIMENTAL
Intervention: Educational program based on Health Belief Model (HBM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 120
Study: 26514967

Group type: EXPERIMENTAL
Intervention: OXC + verapamil (300 mg OXC/12 h and 80 mg verapamil/8 h for 5 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: OXC monotherapy (300 mg OXC/12 h for 5 days)
Number of subjects: 12
Study: 24481580

Group type: EXPERIMENTAL
Intervention: 50 mg dexketoprofen (GD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam (GL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline as placebo (GP)
Number of subjects: 120
Study: 22713851

Group type: EXPERIMENTAL
Intervention: Musical intervention (Study 1, n=22, 3 weeks duration, two sessions per week)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Musical intervention (Study 2, n=11, evaluation 2 and 4 weeks after intervention)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Painting intervention (Study 1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cooking intervention (Study 2)
Number of subjects: 33
Study: 20169301

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Corticosteroid regimen (hydrocortisone acetate 1% ointment for head and neck, hydrocortisone butyrate 0.1% ointment for trunk and limbs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Corticosteroid regimen
Number of subjects: 80
Study: 17570057

Group type: EXPERIMENTAL
Intervention: High dose of Divalproex sodium (DVP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low dose of Divalproex sodium (DVP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (DVP)
Number of subjects: 71
Study: 16251796

Group type: EXPERIMENTAL
Intervention: Prenatal and postnatal fluoride supplements
Number of subjects: 185

Group type: COMPARATOR
Intervention: Postnatal fluoride only
Number of subjects: 185
Study: 12010875

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11045181

Group type: COMPARATOR
Intervention: Fluvastatin 40 mg daily
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combination of fluvastatin (20 mg daily) and fenofibrate (200 mg daily)
Number of subjects: 104
Study: 8736279

Group type: EXPERIMENTAL
Intervention: Full replacement therapy (thyroxine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 micrograms thyroxine daily for 2 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 25 ng/kg/min for 30 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion
Number of subjects: 10
Study: 1895900

Group type: EXPERIMENTAL
Intervention: OTM-01A ophthalmic tonometer
Number of subjects: 42

Group type: COMPARATOR
Intervention: Goldman's tonometer
Number of subjects: 42
Study: 6624778

Group type: COMPARATOR
Intervention: Aerosol albuterol (3 puffs)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral aminophylline (400 mg) and terbutaline sulfate (5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral therapy
Number of subjects: 17
Study: 30700324

Group type: EXPERIMENTAL
Intervention: Intermittent retrospective continuous glucose monitoring (r-CGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27610741

Group type: EXPERIMENTAL
Intervention: Modular evidence-based treatment targeting comorbid mental health problems
Number of subjects: 57

Group type: COMPARATOR
Intervention: Modular evidence-based treatment focusing on principal clinical problems
Number of subjects: 57
Study: 26986774

Group type: EXPERIMENTAL
Intervention: SAX technique (n=25)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: LAX technique (n=26)
Number of subjects: 101
Study: 22917623

Group type: EXPERIMENTAL
Intervention: Incentive trials with monetary reward for correct performance
Number of subjects: 63

Group type: COMPARATOR
Intervention: No-incentive trials without monetary reward
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Higher glucocorticoid (GC) dosage
Number of subjects: 63
Study: 21791470

Group type: EXPERIMENTAL
Intervention: Presence of MAGEA6 and CDCA1
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Presence of MAGEA9
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Presence of CTAG2
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Presence of SSX1
Number of subjects: 584
Study: 18990168

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Hormone therapy (control)
Number of subjects: 3000
Study: 16846539

Group type: EXPERIMENTAL
Intervention: Global risk educational tool
Number of subjects: 368

Group type: COMPARATOR
Intervention: General information on coronary prevention goals and strategies (Control)
Number of subjects: 368
Study: 12766755

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 317

Group type: COMPARATOR
Intervention: Atenolol and hydrochlorothiazide (as adjunct therapy)
Number of subjects: 317
Study: 10699773

Group type: EXPERIMENTAL
Intervention: Transcutaneous carbon dioxide (PtcCO(2)) monitoring guiding sedation (Group 1)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group with PtcCO(2) recorded but not used for guiding sedation (Group 2)
Number of subjects: 395
Study: 9327366

Group type: EXPERIMENTAL
Intervention: Spray-dried bovine serum concentrate (25% replacement of milk protein)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spray-dried bovine serum concentrate (50% replacement of milk protein)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control diet (rice, milk, vegetable oil, and sugar)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spray-dried bovine serum concentrate (25% and 50% replacement)
Number of subjects: 10